<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Hanekamp, E.E.</title>
    <link>http://repub.eur.nl/res/aut/6127/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Progesterone inhibition of Wnt/β-catenin signaling in normal endometrium and endometrial cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/17497/</link>
      <pubDate>2009-09-15T00:00:00Z</pubDate>
      <description>Purpose. Wnt signaling regulates the fine balance between stemness and differentiation. Here, the role of Wnt signaling to maintain the balance between estrogen-induced proliferation and progesterone-induced differentiation during the menstrual cycle, as well as during the induction of hyperplasia and carcinogenesis of the endometrium, was investigated. Experimental Design: Endometrial gene expression profiles from estradiol (E2) and E 2 + medroxyprogesterone acetate-treated postmenopausal patients were combined with profiles obtained during the menstrual cycle (PubMed; GEO DataSets). Ishikawa cells were transfected with progesterone receptors and Wnt inhibitors dickkopf homologue 1 (DKK1) and forkhead box O1 (FOXO1), measuring Wnt activation. Expression of DKK1 and FOXO1 was inhibited by use of sequence-specific short hairpins. Furthermore, patient samples (hormone-treated endometria, hyperplasia, and endometrial cancer) were stained for Wnt activation using nuclear β-catenin and CD44. Results: In vivo, targets and components of the Wnt signaling pathway (among them DKK1 and FOXO1) are regulated by E2 and progesterone. In Wnt-activated Ishikawa cells, progesterone inhibits Wnt signaling by induction of DKK1 and FOXO1. Furthermore, using siRNA-mediated knockdown of both DKK1 and FOXO1, progesterone inhibition of Wnt signaling was partly circumvented. Subsequently, immunohistochemical analysis of the Wnt target gene CD44 showed that progesterone acted as an inhibitor of Wnt signaling in hyperplasia and in well-differentiated endometrial cancer. Conclusion: Progesterone induction of DKK1 and FOXO1 results in inhibition of Wnt signaling in the human endometrium. This Wnt inhibitory effect of progesterone is likely to play a rate-limiting role in the maintenance of endometrial homeostasis and, on its loss, in tumor onset and progression toward malignancy.</description>
    </item> <item>
      <title>Stable RNA markers for identification of blood and saliva stains revealed from whole genome expression analysis of time-wise degraded samples (Article)</title>
      <link>http://repub.eur.nl/res/pub/29988/</link>
      <pubDate>2008-03-01T00:00:00Z</pubDate>
      <description>Human body fluids such as blood and saliva represent the most common source of biological material found at a crime scene. Reliable tissue identification in forensic science can reveal significant insights into crime scene reconstruction and can thus contribute toward solving crimes. Limitations of existing presumptive tests for body fluid identification in forensics, which are usually based on chemoluminescence or protein analysis, are expected to be overcome by RNA-based methods, provided that stable RNA markers with tissue-specific expression patterns are available. To generate sets of stable RNA markers for reliable identification of blood and saliva stains we (1) performed whole-genome gene expression analyses on a series of time-wise degraded blood and saliva stain samples using the Affymetrix U133 plus2 GeneChip, (2) consulted expression databases to obtain additional information on tissue specificity, and (3) confirmed expression patterns of the most promising candidate genes by quantitative real-time polymerase chain reaction including additional forensically relevant tissues such as semen and vaginal secretion. Overall, we identified nine stable mRNA markers for blood and five stable mRNA markers for saliva detection showing tissue-specific expression signals in stains aged up to 180 days of age, expectedly older. Although, all of the markers were able to differentiate blood/saliva from semen samples, none of them could differentiate vaginal secretion because of the complex nature of vaginal secretion and the biological similarity of buccal and vaginal mucosa. We propose the use of these 14 stable mRNA markers for identification of blood and saliva stains in future forensic practice. </description>
    </item> <item>
      <title>Differences in invasive capacity of endometrial cancer cell lines expressing different progesterone receptor isotypes: possible involvement of cadherins (Article)</title>
      <link>http://repub.eur.nl/res/pub/15102/</link>
      <pubDate>2005-05-01T00:00:00Z</pubDate>
      <description>OBJECTIVE: Loss of expression of progesterone receptors (PR) in endometrial cancer is related to a more invasive and metastatic phenotype. In this study we aim to investigate whether selective loss of PRA or PRB affects the invasive capacity of endometrial cancer cells. METHODS: cDNA microarrays were performed to compare gene expression profiles of a set of endometrial cancer sub-cell lines expressing PRA and/or PRB. In vitro invasion assays were performed to assess whether differences in gene expression between the lines were reflected by their invasive behavior. RESULTS: It was observed that cell lines that express only PRA express higher levels of cadherins, and show a lower level of invasion compared to cell lines that express PRB. When cadherin function was inhibited in exclusively PRA-expressing cell lines, an increase of in vitro invasion was observed. In support of these findings, it was observed that in higher grade and more invasive endometrial cancer, expression of E-cadherin decreased. CONCLUSIONS: These results indicate that relative loss of PRA during progression of endometrial cancer can have a negative impact on cadherin expression, which may lead to development of a more metastatic phenotype.</description>
    </item> <item>
      <title>Progestogenic effects of tibolone on human endometrial cancer cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/10130/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>Tibolone, a synthetic steroid acting in a tissue-specific manner and used
      in hormone replacement therapy, is converted into three active
      metabolites: a Delta(4) isomer (exerting progestogenic and androgenic
      effects) and two hydroxy metabolites, 3 alpha-hydroxytibolone (3
      alpha-OH-tibolone) and 3beta-OH-tibolone (exerting estrogenic effects). In
      the present study an endometrial carcinoma cell line (Ishikawa PRAB-36)
      was used to investigate the progestogenic properties of tibolone and its
      metabolites. This cell line contains progesterone receptors A and B, but
      lacks estrogen and androgen receptors. When tibolone was added to the
      cells, complete conversion into the progestogenic/androgenic Delta(4)
      isomer was observed within 6 d. Furthermore, when cells were cultured with
      tibolone or when the Delta(4) isomer or the established progestagen
      medroxyprogesterone acetate was added to the medium, marked inhibition of
      growth was observed. Interestingly, 3 beta-OH-tibolone also induces some
      inhibition of growth. These growth inhibitions were not observed in
      progesterone receptor-negative parental Ishikawa cells, and
      progestagen-induced growth inhibition of PRAB-36 cells could readily be
      reversed using the antiprogestagen Org-31489. Upon measuring the
      expression of two progesterone-regulated genes (fibronectin and
      IGF-binding protein-3), tibolone, the Delta(4) isomer and
      medroxyprogesterone acetate showed similar gene expression regulation.
      These results indicate that tibolone, the Delta(4) metabolite, and to some
      extent 3 beta-OH-tibolone exert progestogenic effects. Tibolone and most
      likely 3 beta-OH-tibolone are converted into the Delta(4) metabolite.</description>
    </item> <item>
      <title>Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer (Article)</title>
      <link>http://repub.eur.nl/res/pub/10230/</link>
      <pubDate>2003-01-01T00:00:00Z</pubDate>
      <description>PURPOSE: In endometrial cancer, loss of progesterone receptors (PR) is
      associated with more advanced disease. This study aimed to investigate the
      mechanism of action of progesterone and the loss of its receptors (PRA and
      PRB) in development of endometrial cancer. EXPERIMENTAL DESIGN: A
      9600-cDNA microarray analysis was performed to study regulation of gene
      expression in the human endometrial cancer subcell line Ishikawa PRAB-36
      by the progestagen medroxy progesterone acetate (MPA). Five MPA-regulated
      genes were selected for additional investigation. Expression of these
      genes was studied by Northern blot and by immunohistochemistry in Ishikawa
      subcell lines expressing different PR isoforms. Additionally, endometrial
      cancer tissue samples were immunohistochemically stained to study the in
      vivo protein expression of the selected genes. RESULTS: In the PRAB-36
      cell line, MPA was found to regulate the expression of a number of
      invasion- and metastasis-related genes. On additional investigation of
      five of these genes (CD44, CSPG/Versican, Tenascin-C, Fibronectin-1, and
      Integrin-beta 1), it was observed that expression and progesterone
      regulation of expression of these genes varied in subcell lines expressing
      different PR isoforms. Furthermore, in advanced endometrial cancer, it was
      shown that loss of expression of both PR and E-cadherin was associated
      with increased expression CD44 and CSPG/Versican. CONCLUSION: The present
      study shows that progestagens exert a modulatory effect on the expression
      of genes involved in tumor cell invasion. As a consequence, loss of PR
      expression in human endometrial cancer may lead to development of a more
      invasive phenotype of the respective tumor.</description>
    </item>
  </channel>
</rss>